

## Ramizol<sup>®</sup>: A new treatment for *Clostridium difficile* associated disease

A scientific paper released today in the *Journal of Antibiotics* presents the pre-clinical development of Ramizol<sup>®</sup>, a first generation drug belonging to a new class of styrylbenzene antibiotics with a novel mechanism of action.

The research was undertaken by Australian company Boulos & Cooper Pharmaceuticals in partnership with the University of South Australia, Flinders University, Eurofins Panlabs and Micromyx LLC. The study found that over 99.9% of the drug, administered orally, stays in the gastrointestinal tract where it can reach the bacteria in the colon at high enough concentrations to yield a therapeutic effect.

Chief Executive Officer of Boulos & Cooper Pharmaceuticals, Dr Ramiz Boulos, said "this new class of antibiotics has antioxidant properties and can be manufactured for a low cost; benefits that will be felt by the end-user".

The new antibiotic has low frequency of resistance and shows promise as a monotherapy for the treatment of *Clostridium difficile* associated disease. Dr Boulos stated "we are very excited about these results given the unforgiving nature of *Clostridium difficile* infections". He added "In a world where there are few treatment options, we are desperate for new antibiotics to fight intractable infections".

The company expects to start Phase I clinical trials in 2017.

Download the paper here: <http://www.nature.com/ja/journal/vaop/ncurrent/full/ja201645a.html>

For further information and images, please contact:

Dr Ramiz Boulos  
Chief Executive Officer  
email: [ceo@bouloscooper.com](mailto:ceo@bouloscooper.com)  
telephone: +61 431 150 538